Entera Bio Ltd. logo
Entera Bio Ltd. ENTX
$ 1.21 -3.97%

Annual report 2020
added 08-19-2023

report update icon

Entera Bio Ltd. Cash Flow 2011-2026 | ENTX

Annual Cash Flow Entera Bio Ltd.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

- -10.4 M -8.92 M -9.8 M -4.53 M -3.14 M - - - - -

All numbers in USD currency

Quarterly Cash Flow Entera Bio Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Entera Bio Ltd., reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.14 0.36 % $ 443 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.41 4.73 % $ 230 M israelIsrael
Ardelyx Ardelyx
ARDX
$ 6.06 1.94 % $ 1.46 B usaUSA
argenx SE argenx SE
ARGX
$ 752.35 0.79 % $ 25 B niderlandNiderland
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.83 0.85 % $ 3.03 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.65 -1.12 % $ 16.6 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
BioCardia BioCardia
BCDA
$ 1.2 -0.04 % $ 8 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 9.6 6.37 % $ 1.98 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 9.48 -3.27 % $ 613 M usaUSA
BioVie BioVie
BIVI
$ 1.45 2.09 % $ 2.14 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.32 4.98 % $ 908 M israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 56.49 1.78 % $ 10.8 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 92.3 1.23 % $ 27.2 B germanyGermany
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 3.04 1.54 % $ 259 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.16 -2.12 % $ 14.2 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.54 9.54 % $ 683 M britainBritain
Cabaletta Bio Cabaletta Bio
CABA
$ 3.2 7.94 % $ 322 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.21 4.56 % $ 6.98 B israelIsrael
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 19.97 2.94 % $ 1.78 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Codexis Codexis
CDXS
$ 1.97 7.97 % $ 172 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 1.91 2.42 % $ 364 M usaUSA
Cullinan Management Cullinan Management
CGEM
$ 15.4 6.72 % $ 928 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.75 0.87 % $ 205 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain